联邦制药(03933.HK) 公布,全资附属珠海联邦制药中山分公司申报的注射用第三代头孢菌素类抗生素经中国国家药品监督管理局审批,通过仿制药质量和疗效一致性评价。该药适用于治疗敏感细菌引起的下呼吸道感染、泌尿生殖道感染、妇科感染、菌血症/败血症、皮肤及皮肤软组织感染、腹腔感染、骨和关节感染及中枢神经系统感染等。 (ha/a)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-15 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.